Berlin-Chemie AG, a member of the Menarini Group, has been granted the exclusive rights to market and sell Moberg Pharma’s Emtrix® in Russia and Ukraine.
The extended distribution agreement builds on an existing collaboration between Moberg and Menarini, which resulted in a successful launch of Emtrix® in Italy. Product launches also have been initiated in China and Southeast Asia. The rights to Emtrix® in Russia were released from a previous distribution agreement with Meda AB. The product was not launched in Russia under the previous agreement.
Berlin-Chemie/Menarini is a leading regional biopharmaceutical company with full national coverage in Russia, a sales force with more than 700 sales representatives and a strong track record of launching and promoting consumer health brands.
“I am very pleased to expand our collaboration with the Menarini Group through this agreement with Berlin-Chemie – a leading marketer in Eastern Europe. The Russian market has significant long-term potential for Moberg’s products,” said Peter Wolpert, CEO of Moberg Pharma AB.
“We look forward to introducing Emtrix® to consumers in Russia. The product has potential to contribute strongly to our expansion within the consumer health market, as it provides rapid relief for a large segment of patients suffering from nail fungus,” said Michael Sirotovich, COO at Berlin-Chemie AG’s International Division.
Source: BioSpace
